A Novel Hydrogen Sulfide-releasing Compound, S-Propargyl Cysteine, Prevents STZ-induced Diabetic Nephropathy

Previous PostLong-term Administration of Two New Alpha-glucosidase Inhibitors in Insulin-dependent Diabetes Patients: Effects on Glycemic Control, Insulin Requirements, and Breath Hydrogen Excretion
Next PostHydrogen-rich Water Supplementation Improves Lipid and Glucose Metabolism in Patients with Type 2 Diabetes or Pre-diabetes

Disclaimer: The medical papers and academic information provided on this site are intended for educational purposes only and are not meant to diagnose, treat, prevent diseases, or substitute for a doctor’s advice.

A Novel Hydrogen Sulfide-releasing Compound, S-Propargyl Cysteine, Prevents STZ-induced Diabetic Nephropathy

Previous PostLong-term Administration of Two New Alpha-glucosidase Inhibitors in Insulin-dependent Diabetes Patients: Effects on Glycemic Control, Insulin Requirements, and Breath Hydrogen Excretion

Next PostHydrogen-rich Water Supplementation Improves Lipid and Glucose Metabolism in Patients with Type 2 Diabetes or Pre-diabetes

Photobiomodulation Treatment device

Hyperbaric Oxygen Chamber

Other Products

About

Learn More

Product Background

References

Get In Touch

Hyperbaric Oxygen
Chamber